Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pei Xiang Xing

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Current Opinion in Molecular Therapeutics|November 7, 2003
Technology evaluation: R-1549, Antisoma/RochePei Xiang Xing
Current Opinion in Investigational Drugs (London, England : 2000)|December 24, 2005
MDX-060. MedarexXiu Feng Hu, Pei Xiang Xing
Expert Opinion on Therapeutic Targets|June 7, 2005
Cripto as a target for cancer immunotherapyXiu Feng Hu, Pei Xiang Xing
Drug News & Perspectives|September 30, 2005
Cripto monoclonal antibodiesXiu Feng Hu, Pei Xiang Xing
Current Opinion in Molecular Therapeutics|February 6, 2004
Discovery and validation of new molecular targets for ovarian cancerXiu Feng Hu, Pei Xiang Xing
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2005
CNTO-328 (Centocor)Jie Li, Xiu Feng Hu, Pei Xiang Xing
Cellular Immunology|October 7, 2011
Anti-Pim-1 mAb inhibits activation and proliferation of T lymphocytes and prolongs mouse skin allograft survivalJie Li, Bruce Edward Loveland, Pei Xiang Xing
Expert Review of Anticancer Therapy|August 24, 2006
MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinomaXiu Feng Hu, Eunice Yang, Jie Li, et al.
The Journal of Biological Chemistry|August 21, 2004
The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpointMalte Bachmann, Hanjo Hennemann, Pei Xiang Xing, et al.
Experimental Hematology|August 26, 2009
Pim-1 expression and monoclonal antibody targeting in human leukemia cell linesJie Li, Xiu Feng Hu, Bruce E Loveland, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Current Opinion in Molecular Therapeutics|November 7, 2003
Technology evaluation: R-1549, Antisoma/RochePei Xiang Xing
Current Opinion in Investigational Drugs (London, England : 2000)|December 24, 2005
MDX-060. MedarexXiu Feng Hu, Pei Xiang Xing
Expert Opinion on Therapeutic Targets|June 7, 2005
Cripto as a target for cancer immunotherapyXiu Feng Hu, Pei Xiang Xing
Drug News & Perspectives|September 30, 2005
Cripto monoclonal antibodiesXiu Feng Hu, Pei Xiang Xing
Current Opinion in Molecular Therapeutics|February 6, 2004
Discovery and validation of new molecular targets for ovarian cancerXiu Feng Hu, Pei Xiang Xing
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2005
CNTO-328 (Centocor)Jie Li, Xiu Feng Hu, Pei Xiang Xing
Cellular Immunology|October 7, 2011
Anti-Pim-1 mAb inhibits activation and proliferation of T lymphocytes and prolongs mouse skin allograft survivalJie Li, Bruce Edward Loveland, Pei Xiang Xing
Expert Review of Anticancer Therapy|August 24, 2006
MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinomaXiu Feng Hu, Eunice Yang, Jie Li, et al.
The Journal of Biological Chemistry|August 21, 2004
The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpointMalte Bachmann, Hanjo Hennemann, Pei Xiang Xing, et al.
Experimental Hematology|August 26, 2009
Pim-1 expression and monoclonal antibody targeting in human leukemia cell linesJie Li, Xiu Feng Hu, Bruce E Loveland, et al.
Pageof 3